A new version of ResearchHub is available.Try it now
Paper
0
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy
Authors
Marianna Fontana,John Berk
Julian Gillmore,Ronald Witteles,Martha Grogan,Brian Drachman,Thibaud Damy,Pablo García‐Pavía,Jörg Täubel,Scott Solomon,Farooq Sheikh,Nobuhiro Tahara,José González‐Costello,Kenichi Tsujita,Caroline Morbach,Zoltán Pozsonyi,Paul Rocchiccioli,Diego Delgado,Wiek Gilst,A. Jabbour,Antoine Bondue,Darae Kim,Olga Azevedo,Steen Poulsen,Ali Yılmaz,Ewa Jankowska,Vincent Algalarrondo,Andrew Slugg,Pushkal Garg,Katherine Boyle,Elena Yureneva,Nancy Silliman,Lanshu Yang,Jihong Chen,Satish Eraly,John Vest
+34 authors
,Mathew MaurerPublished
Aug 30, 2024
Show more
Save
Tip0
TipSave
Abstract
Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a progressive, fatal disease. Vutrisiran, a subcutaneously administered RNA interference therapeutic agent, inhibits the production of hepatic transthyretin.
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.
